Brief: Pluristem Therapeutics Announces FDA Orphan Drug Designation For PLX Cell Therapy
25/09/2018 12:10
Sept 25 (Reuters) - Pluristem Therapeutics Inc PSTI.O :
* PLURISTEM THERAPEUTICS ANNOUNCES FDA ORPHAN DRUG
DESIGNATION FOR
PLX CELL THERAPY FOR THE TREATMENT OF GRAFT FAILURE AND
INCOMPLETE RECOVERY FOLLOWING HEMATOPOIETIC CELL TRANSPLANTATION
* PLURISTEM THERAPEUTICS INC - IN TRIAL, PRIMARY ENDPOINT IS
SAFETY
Source text for Eikon: ID:nGNX4gRMGh
Further company coverage: PSTI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pluri
See all newsBrief: Pluri Chairman And Active Investor Alejandro Weinstein To Acquire Eib Loan, In Strong Vote Of Confidence In The Company
Brief: Ever After Foods Acquires Fishway To Expand Integrated Food Production Technology Platform
NASDAQ RESUMED AT 09:38 AM
NASDAQ RESUMED AT 09:33 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:33 AM